国药集团
SINOPHARM

國藥控股股份有限公司
SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT
PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE YEAR ENDED 31 DECEMBER 2025

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "**Company**") dated 1 April 2026 (the "**Announcement**") in relation to the annual report for the year ended 31 December 2025 (the "**Reporting Period**") of China National Accord Medicines Corporation Ltd. ("**Sinopharm Accord**"), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited accounting data and financial indicators of Sinopharm Accord for the Reporting Period as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".*

PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD

Whether it has retroactive adjustment or restatement on previous accounting data or not
□Yes ☑No

Unit: Yuan
Currency: RMB

Item	2025	2024	Changes of this year compared with last year	2023
Revenue	73,415,858,423.13	74,378,494,389.57	-1.29%	75,477,484,620.31
Net profit attributable to shareholders of the listed company	1,135,926,834.84	642,493,449.76	76.80%	1,599,255,755.53
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	1,095,695,722.62	581,177,195.97	88.53%	1,532,823,526.34
Net cash flow arising from operating activities	1,638,588,925.27	3,271,468,297.03	-49.91%	2,937,138,679.68
Basic earnings per share (Yuan/Share)	2.04	1.15	77.39%	2.87
Diluted earnings per share (Yuan/Share)	2.04	1.15	77.39%	2.87
Weighted average ROE	6.26%	3.67%	Increased by 2.59 percentage points	9.56%

Item	At the end of 2025	At the end of 2024	Changes of this year-end over last year-end	At the end of 2023
Total assets	49,096,270,979.03	47,555,860,415.22	3.24%	47,571,094,779.26
Net assets attributable to shareholders of the listed company	18,609,963,275.57	17,669,528,375.65	5.32%	17,414,808,729.06

Note: During the Reporting Period, Sinopharm Accord has achieved a net profit attributable to shareholders of the listed company of RMB1.136 billion, representing a year-on-year increase of 76.80%. The increase was mainly due to the year-on-year decrease of RMB686 million in asset impairment provision for goodwill and intangible assets as well as the reduction in rigid expenses and costs such as labor cost and rent resulting from store adjustments.

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
1 April 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.